Embolx products enable breakthrough improvements in cancer therapy.
- Stage Full Product Ready
- Industry Medical Devices and Equipment
- Location Los Altos, CA, USA
- Currency USD
- Founded July 2013
- Employees 3
- Website gust.com
Embolx develops transarterial delivery systems for super-selective cancer therapy that enable physicians to deliver anticancer agents directly into the tumor vasculature. Uniquely, Embolx devices use pressure regulation to eliminate non-target delivery & increase drug distribution in the tumor. In the US & EU, 1.5M cases are amenable to this therapy. The company expects revenues in Q1 2015 & to be CF positive on <$5M total paid-in capital.
Mr. Allen started and managed four diagnostic and medical device companies, two from inception to exit (ChemTrak, IP0 & Metrika, Bayer acquisition) the third, Xlumena is still operating and the fourth, Embolx is in the development stage. He holds a degree in Biochemistry from University of California Berkeley, 15 publications, 28 issued and pending patents and six products that are being sold to hospitals, physician offices and over the counter.
Mr. Halstead earned a Master’s degree in Biomedical Engineering and 5 awards for exceptional job performance. He held positions at VISX, Lumenis, Bacchus Vascular, Iridex and Topcon Medical. Mr. Halstead held director positions in both Engineering and Marketing and has led device projects from inception to commercialization. He has 16 years’ experience in medical device engineering, regulatory, physician training and marketing.
Ms. Sikka earned a Master’s degree in Microbiology & Certifications in Biotechnology & Project Management. She held positions at Stanford University, Cellerant Therapeutics & E Systems. Her experience includes managing multifunctional teams, large scale animal studies & simultaneously managing multiple development & manufacturing projects & associated customers. At Embolx, Ms. Sikka manages partnerships, animal studies & clinical studies.
Craig B. Rashkis, FARWELL RASHKIS, LLPCorporate LawyerUnconfirmedJohn Thuong, E Systems TechnologyFinanceUnconfirmed
Rockpoint Capital, Erik CorriganPartnerUnconfirmed